阿德福韦酯联合苦参素胶囊对CHB肝硬化治疗效果及患者HBV-DNA的影响

发布时间：2018-05-15 00:09

  本文选题：乙型肝炎 + 阿德福韦酯　； 参考：《临床医学研究与实践》2016年21期

【摘要】：目的研究和观察阿德福韦酯联合苦参素胶囊治疗慢性乙型肝炎(CHB)肝硬化患者的疗效及对患者DNA载量(HBVDNA)的影响。方法随机选取180例CHB肝硬化患者作为研究对象,依据治疗方式的不同分为单一用药的对照组(90例)和联合用药组(90例),其中对照组给予阿德福韦酯治疗,联合用药组给予阿德福联合苦参素胶囊治疗。所有患者均以48周为1个疗程,比较两组患者的疾病转归及对HBV-DNA的影响。结果治疗后ALT、TBIL复常率及HBeAg转阴率,两组比较差异具有统计学意义(P0.05),但HBeAg/HBeAb血清转换组间比较差异不明显(P0.05)。随着治疗的进行,两组患者的HBVDNA含量呈下降趋势,HBV-DNA转阴率呈上升趋势,第12、24周,联合用药组在HBV-DNA含量及转阴率上显著优于对照组,差异具有统计学意义(P0.05),第36、48周组间比较HBV-DNA含量及转阴率差异无统计学意义(P0.05)。经治疗,两组患者肝纤维化各指标较治疗前均有改善(P0.05)。联合用药组在LN、PC-Ⅲ及Ⅳ-C指标上改善程度与对照组相比,差异具有统计学意义(P0.05),但HA指标比较无明显差异(P0.05)。结论阿德福韦酯联合苦参素胶囊能够抑制乙肝病毒复制,降低HBV-DNA含量,防止肝细胞损伤及肝纤维产生,疗效显著,值得临床推广运用。
[Abstract]:Objective to study the efficacy of adefovir ester combined with matrine capsule in the treatment of chronic hepatitis B (CHB) patients with liver cirrhosis and the effect of adefovir ester combined with matrine capsule on the DNA load and HBV DNA in patients with chronic hepatitis B (CHB). Methods one hundred and eighty patients with CHB cirrhosis were randomly divided into control group (n = 90) and combined group (n = 90). The control group was treated with adefovir dipivoxil. The combined drug group was treated with adrofol combined with matrine capsule. All patients were treated with 48 weeks as a course of treatment. The outcome of the disease and the effect on HBV-DNA were compared between the two groups. Results there was a significant difference between the two groups in the recovery rate of TBIL and the negative rate of HBeAg after treatment, but there was no significant difference between the two groups in HBeAg/HBeAb seroconversion group (P 0.05). With the progress of treatment, the HBVDNA content of the two groups showed a downward trend and the negative rate of HBV-DNA increased. At the 12th week, the HBV-DNA content and the negative conversion rate in the combined treatment group were significantly better than those in the control group, and the positive rate of HBV-DNA in the combined treatment group was significantly higher than that in the control group. The difference was statistically significant (P 0.05). There was no significant difference in the content of HBV-DNA and the rate of negative conversion between the three groups at week 36 (P 0.05). After treatment, each index of hepatic fibrosis in both groups was improved compared with that before treatment. Compared with the control group, the improvement degree of LNN PC- 鈪，

本文编号：1890083